Breast Cancer Clinical Trial
— CIMEROfficial title:
CIMER: Combined Immunotherapies in Metastatic ER+ Breast Cancer
Verified date | September 2020 |
Source | Weill Medical College of Cornell University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Women with Hormone Receptor (HR)+ Human Epidermal growth factor Receptor (HER)2- metastatic breast cancer are eligible to a randomized trial. Patients receiving standard first line therapy for metastatic HR+ Breast cancer(BC) (letrozole+palbociclib) are randomly assigned to also receive Stereotactic Body Radiation Therapy(SBRT) to each metastatic lesion.
Status | Withdrawn |
Enrollment | 0 |
Est. completion date | December 31, 2028 |
Est. primary completion date | December 31, 2025 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years to 90 Years |
Eligibility |
Inclusion Criteria: - Female = 18 years of age pre and post-menopausal - Oligometastatic disease (= 5 sites of disease) - Premenopausal status is defined as either: - Patient had last menstrual period within the last 12 months, OR - If on tamoxifen or toremifene within the past 14 days, plasma estradiol and FSH must be in the premenopausal range per local normal range, OR - In case of therapy induced amenorrhea, plasma estradiol and/or FSH must be in the premenopausal range per local normal range. - Patients who have undergone bilateral oophorectomy are eligible. - Post-menopausal status defined as either 1) at least 2 years without menstrual period or 2) patients older than 50 with serological evidence of post-menopausal status or 3) hysterectomized patients of any age with FSH confirmation of post-menopausal status. - Eastern Cooperative Oncology Group (ECOG) performance status 0-1 - Biopsy proven diagnosis of HR+HER2- metastatic breast cancer. ER expression is >10% - Patient needs to be able to understand and demonstrate willingness to sign a written informed consent document - Hematological WBC = 2000/uL - Absolute neutrophil count (ANC) =1500/µL - Platelets =100 000/µL - Hemoglobin =9.0 g/dL or =5.6 mmol/La Renal Creatinine OR Measured or calculated creatinine clearance (GFR can also be used in place of creatinine or CrCl) =1.5 × ULN OR =30 mL/min for participant with creatinine levels >1.5 × institutional ULN Hepatic Total bilirubin =1.5 ×ULN OR direct bilirubin =ULN for participants with total bilirubin levels >1.5 × ULN - AST (SGOT) and ALT (SGPT) =2.5 × ULN - Coagulation International normalized ratio (INR) OR prothrombin time (PT) - Activated partial thromboplastin time (aPTT) =1.5 × ULN unless participant is receiving anticoagulant therapy if PT or aPTT is within therapeutic range of intended use of anticoagulants Exclusion Criteria: - Active connective tissue disorders, such as lupus or scleroderma requiring flare therapy - Current use of systemic chemotherapy, endocrine therapy or HER2-neu targeted therapy - Male breast cancer patients - Any lesion >5 cm in greatest diameter. - Inability to obtain histologic proof of metastatic breast cancer - Has received previous endocrine or chemotherapy for metastatic breast cancer. - Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of study drug. - Has a known additional malignancy (second primary) that is progressing or has required active treatment within the past 3 years. Note: - - - Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ (e.g. cervical cancer in situ) that have undergone potentially curative therapy are not excluded. - Has active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment. - Has an active infection requiring systemic therapy. Has a known history of Human Immunodeficiency Virus (HIV). Note: No HIV testing is required unless mandated by local health authority. - Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial. - Patients with uncontrolled brain metastases |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Weill Medical College of Cornell University |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of subjects achieving Objective response rate (ORR) will be assessed. | ORR is defined as the percentage of subjects with either a confirmed complete response (CR) or partial response (PR). | End of study, up to 36 months. | |
Primary | Number of Subjects achieving Progression free survival (PFS) | Progression free survival (PFS) is defined as the time from the start of study treatment until the disease progression or death. | End of study, up to 36 months. | |
Primary | Number of subjects achieving Overall survival(OS) will be assessed. | OS is defined as the time from the start of treatment until death. | End of study, up to 36 months. | |
Secondary | Serial levels of Circulating tumor DNA (ctDNA) | serial levels ctDNA can be an early indication of progression | End of study, up to 36 months. | |
Secondary | Circulating tumor DNA (ctDNA) levels | Circulating tumor DNA (ctDNA) levels will be measured to determine baseline cancer heterogeneity and its response to treatment | End of study, up to 36 months. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
Withdrawn |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
Completed |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A |